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Abstract
OBJECTIVE: Lung transplantation is the ultimate treatment option for patients with end-stage cystic ﬁbrosis (CF) lung disease. Despite
poorer reports on survival beneﬁt for CF patients undergoing lung transplantation, several centers, including ours were able to show a
survival beneﬁt. This study compares our center’s experience with 100 consecutive recipients in two different eras.
METHODS: All CF patients who underwent lung transplantation at our center were included (1992–2009). Survival rates were calculated
and compared between the earlier era (before 2000) and later era (since 2000).
RESULTS: CF patients constituted 35% of all transplantations performed at our institution. Mean age at transplantation was 27 years (range
12–52). Fifty-one percent of the patients were female. Waiting list time was lower in the earlier era compared to the later era (p = 0.04).
Lobar transplantation was performed in 10 cases. Thirty-four percent of the cases required downsizing of the graft. In 33% of the cases,
transplantations were done on cardiopulmonary bypass. There were no anastomotic complications. Total intensive care unit stay was
signiﬁcantly lower in the later era compared to earlier era (p = 0.001). The other parameters such as C-reactive protein at the time of trans-
plantation, total cold ischemic time, and total operation time were comparable between the two eras. Overall 30-day mortality was 5%.
The 30-day mortality was signiﬁcantly lower in the second period (p = 0.006). In the earlier era, 3-month, 1-year, and 5-year survival were
85 ± 6%, 77 ± 8%, and 60 ± 9%, respectively, and in the later era improved to 96 ± 2%, 92 ± 3%, and 78 ± 5% (p = 0.03).
CONCLUSION: Improved results obtained in the early postoperative period since 2000 is most likely due to change in surgical manage-
ment approach. Improved surgical outcome for CF patients can be obtained, especially in experienced transplant centers.
Keywords: Cystic ﬁbrosis • Lung transplantation
INTRODUCTION
Lung transplantation is commonly performed for patients with
end-stage cystic ﬁbrosis (CF) lung disease. According to recent
International Society for Heart and Lung Transplantation (ISHLT)
Registry data, CF constitutes the third most common indication
for lung transplantation [1]. Ultimately, it is the only treatment
option which can restore patients with advanced CF lung disease
toward normal respiratory health [2]. Good post-transplant
outcome has been reported from transplant centers worldwide
[2–4]. Despite of transplant-related and medical comorbidities,
prolonged survival and good quality of life have been reported
for CF recipients [4–7].
In our transplant program, CF is the most common indication
constituting 35% of all lung transplantations performed. We sub-
divided our cohort into two groups (before year 2000 and since
2000). We have chosen year 2000 as a cut-off because since
then we have changed our preservation solution, surgical
approach (two separate anterolateral thoracotomies instead of
clamshell incision), as well as routine induction therapy with
basiliximab. We aim to compare era effect in this article. Era
effect has also been shown in ISHLT registry as it shows the sur-
vival beneﬁt among different eras [1]. This study analyzes par-
ticularly the surgical aspects of improved survival among our CF
cohort.
METHODS
We conducted a retrospective cohort study assessing patients
transplanted at our institution from 1992 to 2009, with follow-up
through March 2010. We assessed all recipients with CF, includ-
ing adult and pediatric cases, undergoing lung transplantation. A
total of 100 patients underwent lung transplantation during the
study period. For further comparison, we divided the whole
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cohort into two groups: operations performed before 2000
(early era) and those performed since 2000 (late era).
At our center, we follow the recently published ISHLT guide-
lines regarding referral and selection of lung-transplant candi-
dates [8].
Organ preservation was performed with Euro-Collins solution
(in the early era), thereafter with Perfadex® (Vitrolife, Sweden).
Before antegrade ﬂush, 500-μg prostaglandin E1 was injected
into the pulmonary artery in all cases. Harvesting of the donor
lungs was undertaken en bloc after perfusion. Since 2000, we
also use retrograde ﬂush with Perfadex® at the time of the back-
table preparation. The decision to perform size-reduced lung
transplantation was made in the operating theater during
implantation. Peripheral segmental wedge resections were
undertaken with a commercially available stapler device. For
lobar transplants, lobectomy was done on the back table. For bi-
lateral sequential lung transplants, bilateral trans-sternal anterior
thoracotomy (clamshell incision) or two separate anterolateral
thoracotomies (since 2000) were performed. First, the bronchial
anastomosis was done followed by venous (atrial cuff ) and pul-
monary artery anastomosis. The recipient’s main bronchus was
divided one ring proximal to the upper lobe bronchus branch.
Bronchial arteries were ligated of the peri-bronchial tissue
without electro-coagulation. All dissection on the bronchus was
performed using ‘minimal’ or ‘no touch’ technique to keep the
peri-bronchial tissue intact. The donor bronchus was cut back as
close as possible to the origin of the upper lobe bronchus with
special attention to the peri-bronchial tissue. Absorbable suture
material polydioxanone was used. A continuous suture to the
membranous wall (4/0) and end-to-end anastomosis with inter-
rupted single stitches (3/0) to the cartilaginous part was per-
formed [9].
The decision to perform the operation with or without the
use of cardiopulmonary bypass (CPB) or extracorporeal mem-
brane oxygenation (ECMO) was made according to the hemo-
dynamic and gas-exchange status, including one-lung
ventilation, temporary clamping of the ipsilateral pulmonary
artery, and/or after transplantation of one side.
According to our standard protocol, patients received induc-
tion therapy (anti-thymocyte globulin or basiliximab since 2000)
and triple immunosuppressive therapy, including cyclosporine,
azathioprine or mycophenolate mofetil (since 1997), and pred-
nisone described elsewhere [10]. Anti-infective prophylaxis was
used according to our center’s protocol [10].
In general, CF recipients underwent sinus surgery post-
transplant followed by regular nasal care [11].
Post-transplant management at our center includes routine
surveillance bronchoscopies with trans-bronchial biopsies and
bronchoalveolar lavage during the ﬁrst 6 months after transplant
and regular outpatient clinic follow-up visits as previously
described [3].
Statistical analysis
Descriptive statistics was used, and data are expressed as
mean ± standard deviation. The statistical analysis was performed
with SPSS 15.0 for Windows. Actuarial survival rates were calcu-
lated by Kaplan–Meier method and compared with Breslow
(Generalized Wilcoxon) test. To test for univariate differences in
categorical variables, we used the Fisher’s exact test. The Mann–
Whitney U-test was used to compare continuous variables
between the groups. A p value less than 0.05 (2-tailed) is consid-
ered signiﬁcant. The University Hospital Zurich’s Research Ethics
Committee granted approval for this retrospective study.
RESULTS
During the study period, we performed lung transplantation in
286 patients. Of these recipients, 100 (35%) had CF and were
included in this study. The other indications for lung transplant-
ation in our center are shown in Fig. 1. The mean age was 27
years (range 12–52). Eleven of the recipients were younger than
18 years of age. There were 51 female and 49 male recipients.
The mean follow-up of our cohort was 59.5 months and the
median follow-up was 50.1 (range 3–193.5) months. All patients
but one underwent bilateral sequential lung transplantation. This
one patient had concomitant congenital heart disease and
underwent heart–lung transplantation. Twenty-one patients had
a pneumothorax prior to transplantation. Two patients under-
went pre-transplant bronchial arterial embolization due to
massive hemoptysis. Two recipients were chronically infected
with Burkholderia Cepacia Complex (BCC; undeﬁned genomo-
var). Size reduction was achieved by lobar transplantation
(n = 10) and anatomic or non-anatomic resections (n = 44). On
the right side, the middle lobe was the most commonly resected
lobe (n = 21), followed by lingula resection (n = 17) on the left.
Otherwise, downsizing was achieved by right upper lobectomy
(n = 8), left upper lobectomy (n = 6), left lower lobectomy
(n = 1), and non-anatomic wedge resections (n = 11), respective-
ly (more than 1 size reductions might have been performed in
one recipient). Other than one middle lobectomy, all size reduc-
tions and all of the lobar transplantations were done in the late
era. Age and sex distribution was comparable between the two
eras. However, recipients in the late era had longer waiting list
times and older donors were utilized (Table 1). Nevertheless, in-
tensive care unit (ICU) stay was signiﬁcantly shorter in the late
era. The other donor variables were comparable between the
two eras. We used ECMO more frequently in the late era (30 vs
3 recipients). Two recipients in the late era were on mechanical
ventilation and ECMO, and two patients were on mechanical
ventilation before transplantation. Postoperative ECMO was
needed in two cases.
Re-transplantation was performed in three recipients due to
chronic graft failure and in one due to primary graft dysfunction
(PGD). All re-transplantations were done in the late era.
Figure 1: The number of transplants for CF and for other end-stage lung
disease performed in Zurich Lung Transplant Program between 1992 and
2009 (N = 286). CF: cystic ﬁbrosis (N = 100); EMP: emphysema (N = 76); IPF:
idiopathic pulmonary ﬁbrosis (N = 47); PPH: primary pulmonary hypertension
(N = 22); and OTH: other (N = 41).
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Surgical complications occurred in 30% of the recipients
(Table 2). Postoperative tracheotomy was performed in two in
the early and in 10 recipients in the late era (p = 0.6). There
were no bronchial complications in the whole series of 100
cases.
The 30-day mortality for the overall group was 5%. We lost
four patients in the early (14.8%) and one case (1.4%) in the late
era (p = 0.006). The causes of death were multiple organ failure/
sepsis (n = 3) and PGD/multi-organ failure (MOF) (n = 2).
The 90-day mortality was 8%. We lost only three patients
between day-31 and day-90 postoperative, all of which occurred
in the late era (Table 3).
Overall 28 recipients died, 13 in the early and 15 in the late
era. Causes of death included bronchiolitis obliterans syndrome
(BOS) (n = 11), multiple organ failure/sepsis (n = 12), PGD/MOF/
sepsis (n = 2), post-transplant lymphoproliferative disease (n = 1),
pancreatic cancer (n = 1), and an unknown cause (n = 1).
For the whole group, 1-year and 5-year survival was 88 ± 3
and 72 ± 5, respectively. In the early era, 3-month, 1-year,
3-year, and 5-year survival were 85 ± 6%, 77 ± 8%, 63 ± 9%, and
60 ± 9%, respectively. In the late era, 3-month, 1-year, 3-year,
and 5-year survival improved to 96 ± 2%, 92 ± 3%, 83 ± 5%, and
78 ± 5%, respectively (p = 0.03) (Fig. 2).
DISCUSSION
Lung transplantation is an accepted option for selected pediatric
and adult patients with severe lung disease that have failed to
respond to standard medical and other surgical treatment [12].
Among more than 27 000 lung transplantations reported to the
ISHLT Registry, CF constitutes the third main indication for this
type of treatment [1]. However, at our center, CF is the most
common indication, constituting more than one-third of lung
transplantations performed. In our center, we have traditionally
transplanted more CF recipients than the international average.
This might have been related to our selection choice (local allo-
cation) as well as low number of emphysema patients. Since 1
July 2007 in our country, the allocation system has changed as a
central allocation. Since then, our 35% CF recipients reduced to
Table 2: Postoperative complications for cystic fibrosis
recipients stratified by era
Early era Late era p value
N (%) 10 (37) 20 (27) 0.3
PGD 4 5 0.2
Pleural compl. 7 17 0.7
Lymphocoele 0 2 0.7
Phrenic nerve injury 0 2 0.4
Abdominal compl. 5 12 0.1
Tracheotomy 2 10 6
PGD: primary graft dysfunction; compl.: complication
Table 1: Characteristics for cystic fibrosis lung-transplant recipients stratified by era
Early era Late era p value
N 27 73
Age (years) 27.8 ± 9.4 27 ± 8.4 0.8
Female (N) 17 34 0.2
Height (cm) 166.4 ± 9.9 162.4 ± 9.7 0.03
Weight (kg) 47.2 ± 7.9 47.5 ± 9.4 0.5
BMI (kg/m2) 16.9 ± 1.2 17.7 ± 3.1 0.1
Waiting list time (days) 111.1 ± 95.8 181.5 ± 175.8 0.04
CRP at Tx (mg/l) 41 (3–138) 13.5 (1–106) 0.3
CMV status (R/D)
neg/neg 15 30
neg/pos 4 21
pos/neg 5 9
pos/pos 3 13
Donor PaO2/FiO2 ratio (kPa) 42.9 ± 19.9 42.5 ± 16.6 0.8
Donor age (years) 31.3 ± 12.1 37.7 ± 15.1 0.05
Donor height (cm) 172.6 ± 10.5 172.1 ± 9.9 0.6
Donor weight (kg) 68.7 ± 13.1 69.2 ± 12.5 0.8
Ischemia time; right (min) 225.8 ± 79.1 237.7 ± 78.5 0.4
Ischemia time; left (min) 312.7 ± 76.5 300.2 ± 84.3 0.5
Total operation time (min) 394.2 ± 122.1 411.6 ± 104.9 0.1
Lobar Tx (N) 0 10
CPB or ECMO (N) 3 30
Intubation time (days) median (range) 1 (1–9) 1 (1–163) 0.7
ICU stay (days) median (range) 6 (1–43) 3 (1–163) 0.001
Pre-Tx FEV1 (l) 0.81 ± 0.3 0.84 ± 0.3 0.3
Pre-Tx FEV1 (%) 25.5 ± 5.9 26.1 ± 8.2 0.9
Best FEV1 (l) 3.3 ± 0.8 3.1 ± 0.8 0.1
All values are given as mean ± standard deviation. Tx: transplantation; BMI: body mass index; FEV1: forced expiratory volume in 1 s; ICU: intensive care
unit; PaO2/FiO2: ratio of arterial oxygen partial pressure to fraction of inspired oxygen; CRP: C-reactive protein (mg/l); CMV: Cytomegalovirus; ECMO:
extracorporeal membrane oxygenator; CPB: cardiopulmonary bypass; R/D: recipient/donor; neg: negative; and pos: positive.
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about 30%. Our percentage of idiopathic pulmonary ﬁbrosis
(IPF) recipients underwent lung transplantation increased from
12% to 30% and, in emphysema recipients, decreased from 28%
to 22%. We have chosen year 2000 as a cut-off because since
then we have changed our preservation solution, surgical
approach (bilateral separate thoracotomies instead of clamshell
incision), as well as routine induction therapy with basiliximab.
Most of the early (within the 30 days) deaths following lung
transplantation for CF were caused by sepsis [2]. Our overall 5%
30-day mortality rate is similar or even lower than that of previ-
ously reported CF series which range from 3.5% to 19.2%
(Table 4) [2, 13–18]. In the late era, we only lost one of 73 recipi-
ents (1.4%) within the ﬁrst 30 days post-transplant compared to
four deaths in the early era (14.8%). Causes of death were sepsis/
MOF and PGD3/MOF. The Newcastle Group in the United
Kingdom reported that 26% of deaths were due to sepsis [2].
Moreover, when recipients had preoperative chronic BCC
chronic lung infection, the mortality rate due to sepsis increased
to 36% [2]. High mortality rates have also been reported from
other centers in recipients with BCC following lung transplant-
ation [19, 20]. In our series, we transplanted two recipients with
BCC. One of them died of BOS after 5 years following transplant-
ation. The other one patient is clinically stable and BOS free at 8
years post-transplant.
In other series, the rates of bronchial anastomotic complications
in CF recipients were 2–15% [2, 21, 22]. A zero complication rate for
bronchial anastomoses as achieved in our series has not been
reported by other groups according to our knowledge. Recently,
we have published our bronchial anastomoses data [9]. In a total of
391 bronchial anastomoses at risk, we only had one patient who
required surgical intervention at postoperative day 5. In CF recipi-
ents, hypertrophic bronchial circulation might have played a role
but we think that meticulous surgical technique and infection pre-
vention are the most important points. Another important factor is
that nearly all of the anastomoses have been performed by the
chief of the division (W. Weder) or done with his attendance.
Outcomes following lung transplantation depend on many
complex and interrelated factors [12], which include graft quality
and preservation, the recipient’s preoperative condition, surgical
technique and postoperative care, the effects of long-term
immunosuppression, and comorbidities. Causes of death in the
early period (30-day) after lung transplantation differ from those
that may occur later. PGD, infection (non-cytomegalovirus), car-
diovascular failure, and acute graft rejection are the most
common causes of early postoperative mortality [1].
Donor parameters (standard vs extended), explantation and
preservation technique, preservation solution (extracellular vs
intracellular), and the use of lung protective ventilation are im-
portant issues for the quality of the lung graft. Back-table retro-
grade ﬂush has also been recommended as it might help to
remove embolic material and assure better distribution of ﬂush
solution [23, 24].
In lung-transplant candidates who have experienced pneu-
mothoraces and eventually undergone pleurodesis prior to
transplantation, the operation may be technically more challen-
ging; however, this seems not to have a signiﬁcant inﬂuence on
outcome [25].
The use of CPB during lung transplantation can be necessary
due to preexisting pulmonary hypertension or on an emergency
basis for refractory hypercapnia, pulmonary hypertension,
Table 3: Detailed data for recipients who died within 90 days of transplantation
Case Age Cause of death Preop. MRSA MRPA CPB BCC DM Liver disease Period Survival (days)
1 36 MOF/sepsis No No No No No 1 1
2 24 MOF/sepsis No No No No No 1 3
3 15 MOF/sepsis No No No No No 1 1
4 31 PGD3/MOF No No No No No 1 8
5 20 PGD3/MOF hyperammonemia MRPA B. gladioli Yes No Yes Portal HT 2 3
6 22 PGD3/MO MRSA Yes No Yes 2 33
7 24 PGD3/MOF/sepsis MRPA No No No Portal HT 2 53
8* 36 PGD3 Yes No Yes No 2 34
MOF: multi-organ failure, Preop.: preoperative; MRSA: methicillin resistant Staphylococcus aureus; MRPA: methicillin resistant Pseudomonas aeruginosa; CPB:
cardiopulmonary bypass; BCC: Burkholderia Cepacia Complex; DM: diabetes mellitus; PGD: primary graft dysfunction; *: re-transplantation; HT:
hypertension; 1: early era; and 2: late era.
Figure 2: Cumulative survival (Kaplan–Meier) after lung transplantation in
cystic ﬁbrosis patients stratiﬁed by two eras. Before 2000: early era; and since
2000: late era.
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technical complications, and graft dysfunction. As CPB may lead
to an increased inﬂammatory status, it should be evaluated care-
fully if there is a clear indication to use CPB. The Newcastle Group
uses CPB routinely during lung transplantation, as it is believed
that this technique allows one to perfuse the both lungs simultan-
eously and to control pressure and to avoid circulatory overload
of one lung [2]. At our center, we do not use CPB routinely;
however, we achieve excellent results. The decision to perform
the operation with or without the use of CPB or ECMO was made
according to the hemodynamic and gas-exchange status includ-
ing one-lung ventilation, temporary clamping of the ipsilateral
pulmonary artery, and/or after transplantation of one side.
PGD is the most important complication in the early post-
operative period. It generally occurs within 24 h following trans-
plantation and is characterized by severe impairment of
oxygenation, low pulmonary compliance, and diffuse parenchy-
mal inﬁltrates. It likely results from a combination of events
resulting from brain death of the donor, cold ischemic storage,
preservation, and reperfusion of the graft.
Our series of lung transplantation for CF is one of the largest
reported series in the world with similar 1-year survival rate as
previously reported (Table 4). The best 1-year survival rate so far
has been reported by Spahr et al. (95%) [17]. Their series
included 57 adult recipients, of whom 17.5% were transplanted
while receiving mechanical ventilation. Patients with BCC
chronic lung infection were not included. In our previous publi-
cation, we calculated the overall survival without lung transplant-
ation in our CF recipients [3]. Calculated 5-year survival without
transplantation was 33% and 72% after transplantation which
showed a true survival beneﬁt for transplanted patients. In the
current series, we analyzed our data for survival of CF recipients
versus other recipients with end-stage lung disease who under-
went lung transplantation in our center. We found no difference
between CF and other diagnosis (p = 0.3). This was also valid for
two eras (before 2000 and after 2000).
In conclusion, despite the potential complications of lung
transplantation, CF recipients undergoing lung transplantation in
our center have good quality of life. Further improvements of
post-transplant survival in the recent era at our center are most
likely multifactorial. Better surgical techniques, organ preserva-
tion, and intensive-care management likely play a role. In add-
ition, careful post-transplant management, including rigorous
treatment of airway infections, sinus surgery, and routine nasal
care, long-term therapy with macrolide antibiotics for BOS, and
extracorporeal photopheresis in selected recipients with BOS
and recurrent acute allograft rejection might have contributed to
improved outcomes at our center as well [3].
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Cystic ﬁbrosis (CF) is a formidable genetic disease. Respiratory
physiotherapy, care and management in specialized centres have
considerably lengthened life expectancy.
The advances made in lung transplantation for CF can clearly
be seen in the International Registry. It is particularly true for
highly specialized teams like that of Zurich. CF is their primary
indication for transplantation with excellent results at 1 and 5
years presented in this issue of EJCTS [1]. Improved results have
also been noted for our team [2], which has carried out 185
transplants for CF to date.
Management by teams of specialized paediatricians and pul-
monologists makes it possible to carry out transplantation as late
as possible, but not too late.
Modiﬁcations to the graft allocation systems in the United
States and several European countries allow transplantation of
the most seriously ill patients [3]. Use of grafts with extended
donor criteria, and evaluation of very marginal grafts with an
ex vivo reperfusion machine, should limit preoperative deaths by
increasing the pool of grafts available.
Some problems are speciﬁc to transplantation for CF [4].
The patients are usually underweight which increases the risk of
postoperative mortality [5]. Therefore, a programme of hyper-nutri-
tion and physiotherapy should be set up during the waiting time.
Some patients have a Burkholderia cepacia complex (BCC)
chronic lung infection. A high mortality rate after transplantation
is associated with Burkholderia ceno-cepacia infection (and
these patients are excluded from transplantation in many teams)
but not with non-ceno-cepacia BCC species [6]. Infection with
Burkholderia gladioli increases morbidity.
In case of infection with Mycobacterium abscessus, a multi-
resistant mycobacteria, pre-transplant eradication therapy should
be attempted [7]. Long-term treatment with multiple drugs may
be complicated in the CF patient with severe disease.
In some severe patients listed for transplantation, mechanical
ventilation and extra corporal membrane oxygenation must be
instituted. In these cases, a rise in postoperative mortality has
been reported in the International Registry [8]. However, if trans-
plantation is carried out in the case of pulmonary failure alone,
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